| Patient | Mary Shelley |
|---|---|
| Date of birth | 1974-08-30 |
| Identifiers | MRN HR-NI028-SYN; SSN (made up) 000-28-6194 |
| Document date | 2026-11-01 |
| Author | Rosamund Achterberg-Ilesanmi, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Primary care visit for headaches with episodes of numbness and weakness of the right hand and leg. Concerns: Headaches for about two years, now most mornings, and frightening spells in which her right hand and leg go numb and weak for a few minutes; Afraid of being told it is "only nerves" again, and of losing the use of the hand she writes with; Has lived through many losses and does not want her son burdened; wants to understand everything and decide for herself. [S]
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Levetiracetam 500 mg oral tablet, one tablet by mouth twice a day | One tablet twice a day | Oral route | 2026-03-17 | active | S |
| Dexamethasone 4 mg oral tablet, one tablet twice a day for three days before surgery, then tapered and stopped over ten days after surgery | One tablet twice a day, then tapering | Oral route | 2026-04-04 to 2026-04-17 | completed | S |
| Acetaminophen 500 mg oral tablet, two tablets (1000 mg) by mouth up to three times a day as needed for headache or wound pain, no more than 3000 mg a day | Two tablets up to every 8 hours as needed | Oral route | 2025-09-01 | active | S |
| Ondansetron 4 mg orally disintegrating tablet, one tablet on the tongue every 8 hours as needed for vomiting, for up to two days | One tablet every 8 hours as needed for vomiting | Oral route | 2026-08-11 to 2026-08-13 | completed | S |
| Procedure | Dates | Status | Evidence |
|---|---|---|---|
| Resting 12-lead electrocardiogram: sinus rhythm 74/min, normal intervals | 2026-03-03 to 2026-03-03 | completed | S |
| MRI of the brain with and without gadolinium, with diffusion imaging and MR angiography of the head and neck: a 3.1 x 2.7 x 2.6 cm extra-axial, dural-based, uniformly enhancing mass on the left frontoparietal convexity over the hand area of the precentral gyrus, with a dural tail and a cerebrospinal fluid cleft; moderate vasogenic edema extending 2.5 cm into the white matter; 2 mm midline shift; no infarct, no other lesion; arteries normal. Appearance typical of a meningioma | 2026-03-06 to 2026-03-06 | completed | S |
| Routine EEG with sleep deprivation: intermittent focal slowing and sharp waves over the left central region (C3); no seizure recorded | 2026-03-10 to 2026-03-10 | completed | S |
| Left frontoparietal craniotomy with total excision of the convexity meningioma, its dural attachment, and a margin of dura (Simpson grade I), with neuronavigation and motor mapping; dural graft. Pathology: meningothelial meningioma, CNS WHO grade 1 (1 mitosis per 10 high-power fields, no brain invasion, no atypical features; Ki-67 3 percent; no TERT promoter mutation or CDKN2A/B homozygous deletion) | 2026-04-07 to 2026-04-07 | completed | S |
| MRI of the brain with gadolinium the day after surgery: gross total resection with no residual enhancement; expected postoperative changes; edema smaller | 2026-04-08 to 2026-04-08 | completed | S |
| MRI of the brain with gadolinium three months after surgery: no residual or recurrent tumor; edema resolved; small area of gliosis under the craniotomy | 2026-07-02 to 2026-07-02 | completed | S |
| Date | Vaccine | Status | Evidence |
|---|---|---|---|
| 2025-10-21 | Influenza vaccine, 2025-2026 season | completed | S |
| 2020-06-15 | Tdap vaccine | completed | S |
| 2026-10-20 | Influenza vaccine, 2026-2027 season | completed | S |
| 2026-10-20 | Recombinant zoster vaccine, dose 1 of 2 | completed | S |
| 2026-10-20 | Pneumococcal conjugate vaccine PCV20 | completed | S |
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|---|---|
| About 1811 to 1812 | Painful skin disease of one whole arm at about fourteen, treated with poultices and a sling; diagnosis uncertain | D (CLM-0010) |
| 1815 to 1819 | Four pregnancies carried to birth, the first ending in a premature delivery | D (CLM-0003, CLM-0006) |
| June 1822 | Miscarriage at about three months with near-fatal hemorrhage, treated with ice baths | D (CLM-0007) |
| From 1839 | Recurrent severe headaches with dizziness, pain in the right hand and eye, transient partial paralysis of the right leg and hand, tremors, and convulsive seizures; called psychosomatic, a derangement of the nerves, and neuralgia by her physicians | D (CLM-0012) |
| June 1, 1840 | Ill health and extreme depression recorded in her journal | D (CLM-0011) |
| Relative | Condition | Age at death | Evidence |
|---|---|---|---|
| mother | Died of puerperal fever eleven days after giving birth to her, after a retained placenta | D (CLM-0002) |
| Concern | Status | Evidence |
|---|---|---|
| Headaches for about two years, now most mornings, and frightening spells in which her right hand and leg go numb and weak for a few minutes | active | S |
| Afraid of being told it is "only nerves" again, and of losing the use of the hand she writes with | active | S |
| Has lived through many losses and does not want her son burdened; wants to understand everything and decide for herself | active | S |
Most recent measures: Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 4 on 2026-09-29; Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] 5 on 2026-07-07; Total score [MoCA] 29 on 2026-09-29; Sodium [Moles/volume] in Serum or Plasma 136 on 2026-08-11; Potassium [Moles/volume] in Serum or Plasma 3.6 on 2026-08-11; Carbon dioxide, total [Moles/volume] in Serum or Plasma 25 on 2026-03-03; Urea nitrogen [Mass/volume] in Serum or Plasma 22 on 2026-08-11; Creatinine [Mass/volume] in Serum or Plasma 0.91 on 2026-08-11; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 95 on 2026-09-29; Glucose [Mass/volume] in Serum or Plasma 88 on 2026-08-11; Calcium [Mass/volume] in Serum or Plasma 9.3 on 2026-03-03; Hemoglobin [Mass/volume] in Blood 12.1 on 2026-04-28; Leukocytes [#/volume] in Blood by Automated count 6.1 on 2026-03-03; Platelets [#/volume] in Blood by Automated count 248 on 2026-03-17; Thyrotropin [Units/volume] in Serum or Plasma 1.9 on 2026-03-03; INR in Platelet poor plasma by Coagulation assay 1 on 2026-03-17; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 0 on 2026-10-20; Total score [AUDIT-C] 1 on 2026-10-20 [S]
Strengths and supports: Supports: a few close friends, her publisher, and her son and daughter-in-law; finds meaning in her work [S]
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Headaches, worse in the morning, for about two years, with episodes over six months of tingling and weakness of the right hand and leg lasting a few minutes, one with twitching of the right fingers and one with difficulty finding words; mild right-hand weakness on examination; cause not yet established; urgent MRI and EEG booked | resolved | confirmed | R29.818 | S — Synthetic presenting concern at the index visit, superseded by the MRI and EEG diagnosis; her documented headaches with transient right-sided paralysis from 1839 are echoed. |
| Meningioma of the left frontoparietal convexity over the hand area of the motor cortex, 3.1 x 2.7 x 2.6 cm, with moderate vasogenic edema; resected (Simpson grade I); meningothelial meningioma, CNS WHO grade 1; synthetic modern counterpart of the supposed tumour of the left hemisphere on her death certificate | active | confirmed | D32.0 | S — Synthetic modern diagnosis. Her symptoms and the certificate's wording are documented (D); a brain tumour is a retrospective interpretation (R) disputed by the hemiplegic migraine and stroke hypothesis, and no tissue exists, so this meningioma is not presented as her historical diagnosis. |
| Focal epilepsy due to the left convexity meningioma: focal aware sensory and motor seizures of the right hand and arm, one with speech arrest; EEG with left central sharp waves; on levetiracetam | active | confirmed | G40.109 | S — Synthetic modern diagnosis echoing her documented convulsive seizures and transient right-sided paralysis; the hemiplegic migraine interpretation is recorded as R. |
| Acute viral gastroenteritis for two days, with vomiting of one levetiracetam dose, mild dehydration, and no seizure; resolved in four days | resolved | confirmed | A08.4 | S — Synthetic common illness chosen to teach antiseizure medicine adherence during vomiting; it echoes no documented illness. |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-03-03 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 7 | {score} | S | ||
| 2026-03-03 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 8 | {score} | S | ||
| 2026-03-03 | Total score [MoCA] | 27 | {score} | S | ||
| 2026-03-03 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-03-03 | Potassium [Moles/volume] in Serum or Plasma | 4.1 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-03-03 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 25 | mmol/L | 22-29 mmol/L | Normal | S |
| 2026-03-03 | Urea nitrogen [Mass/volume] in Serum or Plasma | 13 | mg/dL | 6-21 mg/dL | Normal | S |
| 2026-03-03 | Creatinine [Mass/volume] in Serum or Plasma | 0.74 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 2026-03-03 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 98 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-03-03 | Glucose [Mass/volume] in Serum or Plasma | 91 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-03-03 | Calcium [Mass/volume] in Serum or Plasma | 9.3 | mg/dL | 8.6-10.3 mg/dL | Normal | S |
| 2026-03-03 | Hemoglobin [Mass/volume] in Blood | 12.8 | g/dL | 12-15.5 g/dL | Normal | S |
| 2026-03-03 | Leukocytes [#/volume] in Blood by Automated count | 6.1 | 10*3/uL | 3.4-9.6 10*3/uL | Normal | S |
| 2026-03-03 | Platelets [#/volume] in Blood by Automated count | 252 | 10*3/uL | 157-371 10*3/uL | Normal | S |
| 2026-03-03 | Thyrotropin [Units/volume] in Serum or Plasma | 1.9 | m[IU]/L | 0.4-4 mIU/L | Normal | S |
| 2026-03-17 | INR in Platelet poor plasma by Coagulation assay | 1 | {INR} | 0.8-1.2 | Normal | S |
| 2026-03-17 | Hemoglobin [Mass/volume] in Blood | 12.7 | g/dL | 12-15.5 g/dL | Normal | S |
| 2026-03-17 | Platelets [#/volume] in Blood by Automated count | 248 | 10*3/uL | 157-371 10*3/uL | Normal | S |
| 2026-03-17 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 8 | {score} | S | ||
| 2026-04-28 | Glucose [Mass/volume] in Serum or Plasma | 96 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-04-28 | Sodium [Moles/volume] in Serum or Plasma | 138 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-04-28 | Hemoglobin [Mass/volume] in Blood | 12.1 | g/dL | 12-15.5 g/dL | Normal | S |
| 2026-04-28 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 9 | {score} | S | ||
| 2026-07-07 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 6 | {score} | S | ||
| 2026-07-07 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 5 | {score} | S | ||
| 2026-09-29 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 4 | {score} | S | ||
| 2026-09-29 | Total score [MoCA] | 29 | {score} | S | ||
| 2026-09-29 | Creatinine [Mass/volume] in Serum or Plasma | 0.76 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 2026-09-29 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 95 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-08-11 | Sodium [Moles/volume] in Serum or Plasma | 136 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-08-11 | Potassium [Moles/volume] in Serum or Plasma | 3.6 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-08-11 | Urea nitrogen [Mass/volume] in Serum or Plasma | 22 | mg/dL | 6-21 mg/dL | High | S |
| 2026-08-11 | Creatinine [Mass/volume] in Serum or Plasma | 0.91 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 2026-08-11 | Glucose [Mass/volume] in Serum or Plasma | 88 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-10-20 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S | ||
| 2026-10-20 | Total score [AUDIT-C] | 1 | {score} | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-03-03 | Body height | 160 | cm | S |
| 2026-03-03 | Body weight | 57.2 | kg | S |
| 2026-03-03 | Body mass index (BMI) [Ratio] | 22.3 | kg/m2 | S |
| 2026-03-03 | Systolic blood pressure | 124 | mm[Hg] | S |
| 2026-03-03 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 2026-03-03 | Heart rate | 76 | /min | S |
| 2026-03-03 | Respiratory rate | 14 | /min | S |
| 2026-03-03 | Body temperature | 36.7 | Cel | S |
| 2026-03-03 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 2026-03-17 | Body height | 160 | cm | S |
| 2026-03-17 | Body weight | 57 | kg | S |
| 2026-03-17 | Body mass index (BMI) [Ratio] | 22.3 | kg/m2 | S |
| 2026-03-17 | Systolic blood pressure | 128 | mm[Hg] | S |
| 2026-03-17 | Diastolic blood pressure | 80 | mm[Hg] | S |
| 2026-03-17 | Heart rate | 80 | /min | S |
| 2026-03-17 | Respiratory rate | 14 | /min | S |
| 2026-03-17 | Body temperature | 36.6 | Cel | S |
| 2026-03-17 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 2026-04-28 | Body height | 160 | cm | S |
| 2026-04-28 | Body weight | 58.1 | kg | S |
| 2026-04-28 | Body mass index (BMI) [Ratio] | 22.7 | kg/m2 | S |
| 2026-04-28 | Systolic blood pressure | 122 | mm[Hg] | S |
| 2026-04-28 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-04-28 | Heart rate | 74 | /min | S |
| 2026-04-28 | Respiratory rate | 14 | /min | S |
| 2026-04-28 | Body temperature | 36.6 | Cel | S |
| 2026-04-28 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 2026-07-07 | Body height | 160 | cm | S |
| 2026-07-07 | Body weight | 57.6 | kg | S |
| 2026-07-07 | Body mass index (BMI) [Ratio] | 22.5 | kg/m2 | S |
| 2026-07-07 | Systolic blood pressure | 118 | mm[Hg] | S |
| 2026-07-07 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 2026-07-07 | Heart rate | 70 | /min | S |
| 2026-07-07 | Respiratory rate | 14 | /min | S |
| 2026-07-07 | Body temperature | 36.6 | Cel | S |
| 2026-07-07 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 2026-09-29 | Body height | 160 | cm | S |
| 2026-09-29 | Body weight | 57.4 | kg | S |
| 2026-09-29 | Body mass index (BMI) [Ratio] | 22.4 | kg/m2 | S |
| 2026-09-29 | Systolic blood pressure | 118 | mm[Hg] | S |
| 2026-09-29 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 2026-09-29 | Heart rate | 68 | /min | S |
| 2026-09-29 | Respiratory rate | 14 | /min | S |
| 2026-09-29 | Body temperature | 36.5 | Cel | S |
| 2026-09-29 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 2026-08-11 | Body height | 160 | cm | S |
| 2026-08-11 | Body weight | 56.3 | kg | S |
| 2026-08-11 | Body mass index (BMI) [Ratio] | 22 | kg/m2 | S |
| 2026-08-11 | Systolic blood pressure | 108 | mm[Hg] | S |
| 2026-08-11 | Diastolic blood pressure | 70 | mm[Hg] | S |
| 2026-08-11 | Heart rate | 96 | /min | S |
| 2026-08-11 | Respiratory rate | 16 | /min | S |
| 2026-08-11 | Body temperature | 37.6 | Cel | S |
| 2026-08-11 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-10-20 | Body height | 160 | cm | S |
| 2026-10-20 | Body weight | 57.5 | kg | S |
| 2026-10-20 | Body mass index (BMI) [Ratio] | 22.5 | kg/m2 | S |
| 2026-10-20 | Systolic blood pressure | 120 | mm[Hg] | S |
| 2026-10-20 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-10-20 | Heart rate | 70 | /min | S |
| 2026-10-20 | Respiratory rate | 14 | /min | S |
| 2026-10-20 | Body temperature | 36.6 | Cel | S |
| 2026-10-20 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Purpose | Status | Provenance |
|---|---|---|---|
| 2026-03-03 | Primary care visit for headaches with episodes of numbness and weakness of the right hand and leg | finished | S |
| 2026-03-17 | MRI and EEG results, start of levetiracetam, and neurosurgical consultation | finished | S |
| 2026-04-28 | Review three weeks after craniotomy, with the pathology | finished | S |
| 2026-07-07 | Three-month MRI review after resection | finished | S |
| 2026-09-29 | Six-month review after resection: seizures, mood, and writing | finished | S |
| 2026-08-11 | Same-day sick visit for vomiting and diarrhea on levetiracetam | finished | S |
| 2026-10-20 | Adult preventive visit | finished | S |
| Intervention | Status | Guideline | Provenance |
|---|---|---|---|
| Urgent MRI of the brain with and without gadolinium, with diffusion imaging and MR angiography of the head and neck, within three days; EEG within a week; ECG, blood count, metabolic panel, calcium, and TSH today; headache and episode diary | completed | GL-AAN-SEIZ-2015, GL-NCCN-CNS-2025 | S |
| Safety now: no driving until the cause is known and her seizures are controlled for the period her state requires; showers rather than baths, no swimming alone, and no work at heights; seizure first aid explained; come at once for a longer episode, weakness that does not recover, or a severe sudden headache | completed | GL-AAN-SEIZ-2015 | S |
| Neurosurgery consultation if the MRI shows a structural lesion, to explain the options and their risks to her and plan treatment with her | completed | GL-NCCN-CNS-2025 | S |
| Grief and mood: a grief history, PHQ-9 and GAD-7 at each visit, and the neuro-oncology counselor offered; no assumption that her symptoms are "nerves" | completed | GL-USPSTF-DEP-2023, GL-CMID-2026 | S |
| Protect her writing: occupational therapy assessment of hand function if weakness persists, and voice dictation as a backup | completed | GL-NCCN-CNS-2025 | S |
| Levetiracetam 500 mg twice a day for focal epilepsy due to the meningioma; seizure diary; ask about irritability and low mood at each visit; continue for at least a year after surgery, then decide with her whether to taper after an EEG | completed | GL-AAN-SEIZ-2015, GL-ILAE-EPI-2014, GL-SNO-ASM-2021 | S |
| Shared decision: resection by craniotomy aiming at Simpson grade I, her choice after observation (not advised for a symptomatic tumor with edema and seizures) and stereotactic radiosurgery (less suitable at 3.1 cm with edema next to the motor cortex) were explained; dexamethasone 4 mg twice a day from three days before surgery, tapered and stopped after it; MRI within 48 hours after surgery | completed | GL-EANO-MEN-2021, GL-NCCN-CNS-2025 | S |
| After resection of a CNS WHO grade 1 meningioma (Simpson grade I): no radiation; MRI at three months and then yearly for five years, then every two years; no progestin-containing hormone therapy without discussion | completed | GL-EANO-MEN-2021, GL-NCCN-CNS-2025 | S |
| Goal | Target | Status | Outcome | Provenance |
|---|---|---|---|---|
| A diagnosis within two weeks, explained in plain words with the images and reports | 2026-03-17 | completed | MRI and EEG within a week; diagnosis explained at two weeks with the images | S |
| No further seizures | 2027-04-07 | active | No seizure since the craniotomy | S |
| Full use of the right hand and return to writing every morning | 2026-09-29 | completed | Grip equal on both sides by three months; writing every morning | S |
| Decide on treatment herself after hearing the options, benefits, and harms | 2026-03-17 | completed | Chose resection after observation and radiosurgery were explained | S |
| Mood and grief supported: PHQ-9 below 5 and a counselor available | 2026-09-29 | completed | PHQ-9 4 at six months; completed eight sessions with the neuro-oncology counselor | S |